The mission of our school is both to teach students how to become successful scientists and to undertake world class research focused on turning science into medicine. We strive to ensure direct alignment of our teaching and research expertise, specialising in cancer biology, infection and immunity and regenerative medicine/stem cell biology. This alignment allows us to deliver teaching to our own science undergraduates, to science undergraduates from other schools and to medical and dental students that is informed by cutting-edge research and to establish research programmes that are grounded in the latest expertise in the field.
We pride ourselves on the exceptional abilities of our students when they are admitted to our degree programmes and the excellence of our teaching that leads to a consistently high quality of graduate emerging from the programmes. The quality of teaching was recognised when we scored a maximum 24 out of 24 by the Quality Assurance Agency for Higher Education in their last assessment. (For this review, the school, formerly known as "Pathology and Microbiology", was grouped together with the School of Biochemistry as "molecular biosciences" [Adobe pdf download, 52 Kb].)
Our school is an ideal place for postgraduate students to learn rigorous scientific method through their training and research. All research students are mentored by experienced supervisors and all research programmes are embedded within one of the three broad research themes, providing a critical mass of scientists working on related topics. The “destinations of leavers” statistics that are available for the UK based PhD students who graduated between 2004 and 2009 show that 80% of our PhD graduates go on to work in a research related environment.
Our goal; "turning science into medicine...
Turning science into medicine is our core research mission and to achieve this ambitious aim we must undertake the fundamental science needed to progress ideas through to clinical trials or commercial development. Two recent examples of successful translational research pathways within the school are:
We also aim to exploit our research discoveries through patent protection and by the formation of spin-out companies. We currently have spin-out companies that are developing immunomodulatory molecules for autoimmune diseases, stem cells for the prevention of osteoarthritis and providing platform technologies for drug efficacy trials in immune diseases.
I hope you will find our web pages interesting.
- Anthony Hollander, Professor of Rheumatology and Tissue Engineering and Head of School